For Immediate Release

Chicago, IL – September 3, 2009 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novavax (NVAX), AstraZeneca (AZN), GlaxoSmithKline (GSK), Novartis (NVS) and Sanofi-Aventis (SNY).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Wednesday’s Analyst Blog:

Good News for Novavax

We are pleased to hear that the vaccine developer Novavax (NVAX) has made a major breakthrough in a phase II clinical trial of its trivalent seasonal influenza virus-like particle (VLP) vaccine candidate. While the trial carried out on 221 people (aged 18 to 49 years) showed strong immune system responses against three flu strains (H3N2, H1N1, and B), no major adverse events were reported.

Given the success of the mid-stage trial, Novavax now plans to initiate a study in elderly adults by the fourth quarter and a phase III study next year. Although the progress made by Novavax is positive news, the vaccine is not likely to hit the market in the next few years. Hence, the vaccine will not be of much use in the current pandemic.

Any development on the influenza vaccine front is welcome news as a second wave of swine flu is expected to hit with the onset of winter in the northern hemisphere. It is estimated that globally about 5% to 20% of the population are infected from seasonal flu, killing as many as 250,000-500,000 people each year. According to the World Health Organization (WHO), up to a third of the world’s population may be infected with swine flu this year, with about 15% of them requiring hospital care.

In another development, Chinese vaccine makers Sinovac Biotech and Hualan Biological Engineering expect their swine flu vaccines to be approved by the Chinese authorities this week. The most interesting aspect of this vaccine is that contrary to the earlier expectation that two doses of vaccine would be necessary; both companies have proved the effectiveness of the vaccine in single doses. While Sinovac expects to produce 30 million doses of the vaccine in a year, Hualan plans to produce up to 160 million doses.

According to the Centers for Disease Control, swine flu has become the world’s fastest-moving influenza pandemic, sweeping across 177 countries in the four months since it was first identified. Currently, AstraZeneca (AZN), GlaxoSmithKline (GSK), Novartis (NVS) and Sanofi-Aventis (SNY), supply seasonal flu vaccine in the US market. Many of these have started clinical testing of their swine flu vaccines recently.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Mark Vickery
Web Content Editor



Zacks Investment Research